1 completed, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Gallium: new trials by email Literature Review of Gallium trials Research Report on Gallium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg) - Oligometastatic Prostate Cancer (OMPC) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 450 | 2024-03-12 | 2026-10-21 |
| 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography - Prostate Adenocarcinoma | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 122 | 2015-11-16 | 2023-04-10 |
Andrei Iagaru (1) · Novartis Pharmaceuticals (1)
United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Colombia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1)
Andrei Iagaru (1)